Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
46 results about "Phenytoin" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Phenytoin is used to prevent and control seizures (also called an anticonvulsant or antiepileptic drug).
Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
A pharmaceutical composition comprising a co-crystal of an API and a co-crystal former; wherein the API has at least one functional group selected from ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphinic acid, phosphonic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, imine, thiocyanate, cyanamide, oxime, nitrile diazo, organohalide, nitro, S-heterocyclic ring, thiophene, N-heterocyclic ring, pyrrole, 0-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, pyridine and the co-crystal former has at least one functional group selected from amine, amide, pyridine, imidazole, indole, pyrrolidine, carbonyl, carboxyl, hydroxyl, phenol, sulfone, sulfonyl, mercapto and methyl thio, such that the API and co-crystal former are capable of co-crystallizing from a solution phase under crystallization conditions.
Owner:UNIV OF SOUTH FLORIDA +3
Phenytoin Formulations, and Uses Thereof in Wound Healing
InactiveUS20090022779A1Promote wound healingCut woundOrganic active ingredientsPowder deliveryWound healingPhenylbutyrate
A formulation of phenyloin suitable for topical application to a wound comprises a reservoir of phenyloin entrapped within a stabilising matrix, and an amount of dissolved phenyloin, wherein the dissolved phenyloin is in chemical equilibrium with the phenyloin entrapped within the stabilised matrix. The stabilised matrix may comprise a gel matrix, especially a gel matrix in which the polymer of the gel forms ion-pairs with the phenyloin. Also described are methods of treating a wound in diabetic and non-diabetic patients using a formulation according to the invention.
Owner:ROYAL COLLEGE OF SURGEONS & IRELAND
Treatments for viral infections
InactiveUS20050245502A1Effective treatmentReduced activityBiocideAnimal repellantsViral infectionMultiple vitamins
The present invention relates to improved methods and compositions for treating viral infections. More particularly, the present invention relates to novel compositions comprising an anti-convulsant, such as phenytoin, in combination with multivitamins as an anti-viral composition and methods of use thereof.
Owner:PHOENIX BIOSCI
Phenytoin therapy
InactiveUS6110499AImprove solubilityIncrease moistureOrganic active ingredientsPill deliveryPhysical therapyDosage form
A therapeutic composition, a dosage form and a method are disclosed for administering phenytoin indicated for the management of epilepsy.
Owner:ENCINAL PHARMA INVESTMENTS
Method and system for the prediction of cardiac arrhythmias, myocardial ischemia, and other diseased condition of the heart associated with elevated sympathetic neural discharges
InactiveUS20060074451A1Raise the possibilityIncrease heart rateSpinal electrodesHeart stimulatorsDiseaseAntiarrhythmic effect
Methods and systems are provided for determining an increased likelihood of the occurrence of a cardiac arrhythmia, myocardial ischemia, congestive heart failure and other diseased conditions of the heart associated with elevated sympathetic neural discharges in a patient. The methods and systems comprise monitoring the sympathetic neural discharges of a patient from the stellate ganglia, the thoracic ganglia, or both, and detecting increases in the sympathetic neural discharges. The methods and systems may further comprise delivering therapy to the patient in response to a detected increase in the sympathetic neural discharge, such as delivering one or more pharmacological agents; stimulating myocardial hyperinnervation in the sinus node and right ventricle of the heart of the patient; and applying cardiac pacing, cardioversion or defibrillation shocks. Pharmacologic agents which may be used in connection with the delivery of include those which are known to exert anti-arrhythmic effect and anti-convulsant agents, such as phenytoin, carbamazepine, valproate, and phenobarbitone. Other pharmacologic agents may be used to treat impending myocardial ischemia and other diseased conditions of the heart associated with elevated sympathetic neural discharges.
Owner:CEDARS SINAI MEDICAL CENT
Phenytoin therapy
InactiveUS6346270B1Improve solubilityIncrease moisturePowder deliveryOrganic active ingredientsPhysical therapyDosage form
A therapeutic composition, a dosage form and a method are disclosed for administering phenytoin indicated for the management of epilepsy.
Owner:ENCINAL PHARMA INVESTMENTS
Topical therapies for oral mucositis and other conditions
InactiveUS20080299050A1Inhibit mucosal degenerationPromote mucosal regenerationCosmetic preparationsBiocideDiseaseTopical treatment
A method for treating oral mucositis in a subject comprises topically administering to an oral mucosal surface of the subject phenyloin or a pharmaceutically acceptable salt thereof in an amount effective to inhibit mucosal degeneration or promote mucosal regeneration, and optionally an analgesic agent in an amount effective, in combination with the phenyloin or salt thereof, to reduce pain associated with the oral mucositis. The phenyloin or salt thereof and optionally the analgesic agent can be administered in a pharmaceutical composition comprising an excipient vehicle suitable for intraoral administration, said composition being bioadhesive to an oral mucosal surface, for example having at least one non-lipoidal internal phase and at least one lipoidal external phase that is bioadhesive to said surface.
Owner:DRAGTEK CORP
Treatments for viral infections
InactiveUS7479498B2Effective treatmentReduced activityBiocideOrganic chemistryDiseaseViral infection
The present invention relates to improved methods and compositions for treating viral infections and other diseases and conditions that induce a cytokine storm. More particularly, the present invention relates to novel compositions comprising quercitin, and an anti-convulsant, such as phenytoin, in combination with mulivitamins as an anti-viral composition and methods of use thereof.
Owner:PHOENIX BIOSCI
Method and system for the prediction of cardiac arrhythmias, myocardial ischemia, and other diseased condition of the heart associated with elevated sympathetic neural discharges
Owner:CEDARS SINAI MEDICAL CENT
Phenytoin derivative as well as preparation method and application thereof
ActiveCN104016923AGood antibacterial effectImprove the bactericidal effectAntibacterial agentsOrganic active ingredientsWound healingMedicine
The invention provides a phenytoin derivative with a structure (I), a preparation method of the phenytoin derivative, application of the phenytoin derivative to preparation of externally-applied medicaments for promoting wound healing and inhibiting bacterial wound infection, and the externally-applied medicaments for promoting the wound healing and inhibiting the wound infection. The structure (I) is as shown the specification.
Owner:NANKAI UNIV
Method and system for the prediction of cardiac arrhythmias, myocardial ischemia, and other diseased condition of the heart associated with elevated sympathetic neural discharges
InactiveUS20060004414A1Raise the possibilityIncrease heart rateCatheterHeart stimulatorsDiseaseAntiarrhythmic effect
Methods and systems are provided for determining an increased likelihood of the occurrence of a cardiac arrhythmia, myocardial ischemia, congestive heart failure and other diseased conditions of the heart associated with elevated sympathetic neural discharges in a patient. The methods and systems comprise monitoring the sympathetic neural discharges of a patient from the stellate ganglia, the thoracic ganglia, or both, and detecting increases in the sympathetic neural discharges. The methods and systems may further comprise delivering therapy to the patient in response to a detected increase in the sympathetic neural discharge, such as delivering one or more pharmacological agents; stimulating myocardial hyperinnervation in the sinus node and right ventricle of the heart of the patient; and applying cardiac pacing, cardioversion or defibrillation shocks. Pharmacologic agents which may be used in connection with the delivery of include those which are known to exert anti-arrhythmic effect and anti-convulsant agents, such as phenytoin, carbamazepine, valproate, and phenobarbitone. Other pharmacologic agents may be used to treat impending myocardial ischemia and other diseased conditions of the heart associated with elevated sympathetic neural discharges.
Owner:CEDARS SINAI MEDICAL CENT
Treatments for viral infections
InactiveUS20060241059A1Effective treatmentReduced activityBiocideOrganic chemistryViral infectionDisease cause
The present invention relates to improved methods and compositions for treating viral infections and other diseases and conditions that induce a cytokine storm. More particularly, the present invention relates to novel compositions comprising quercitin, and an anti-convulsant, such as phenytoin, in combination with mulivitamins as an anti-viral composition and methods of use thereof.
Owner:PHOENIX BIOSCI
Method and system for the prediction of cardiac arrhythmias, myocardial ischemia, and other diseased condition of the heart associated with elevated sympathetic neural discharges
Methods and systems are provided for determining an increased likelihood of the occurrence of a cardiac arrhythmia, myocardial ischemia, congestive heart failure and other diseased conditions of the heart associated with elevated sympathetic neural discharges in a patient. The methods and systems comprise monitoring the sympathetic neural discharges of a patient from the stellate ganglia, the thoracic ganglia, or both, and detecting increases in the sympathetic neural discharges. The methods and systems may further comprise delivering therapy to the patient in response to a detected increase in the sympathetic neural discharge, such as delivering one or more pharmacological agents; stimulating myocardial hyperinnervation in the sinus node and right ventricle of the heart of the patient; and applying cardiac pacing, cardioversion or defibrillation shocks. Pharmacologic agents which may be used in connection with the delivery of include those which are known to exert anti-arrhythmic effect and anti-convulsant agents, such as phenytoin, carbamazepine, valproate, and phenobarbitone. Other pharmacologic agents may be used to treat impending myocardial ischemia and other diseased conditions of the heart associated with elevated sympathetic neural discharges.
Owner:CEDARS SINAI MEDICAL CENT
Wound healing compositions based on cyanoacrylates and 5,5-disubstitutedhydantoins, including phenytoin
ActiveUS8287901B2Improves wound healingGood techniqueSurgical adhesivesAdhesive dressingsCyanoacrylateMedicine
Owner:ADHEZION BIOMEDICAL
Biomarker for forecasting severe drug-induced cutaneous adverse reaction of child patient and application
The invention discloses a biomarker for forecasting severe drug-induced cutaneous adverse reaction of a child patient and an application. The biomarker is capable of forecasting the risk of severe cutaneous adverse reaction of the child patient using beta-lactam antibiotics such as penicillin, cephalosporin, carbamazepine, lamotrigine, oxcarbazepine, phenytoin, allopurinol, nevirapine, abacavir, methazolamide and dapsone.
Owner:THE THIRD XIANGYA HOSPITAL OF CENT SOUTH UNIV
P-glycoprotein monoclonal antibody modified phenytoin targeting nanopreparation and preparation method thereof
InactiveCN102125522AImprove securityGood biocompatibilityOrganic active ingredientsNervous disorderPolyethylene glycolTherapeutic effect
The invention belongs to medical preparations and relates to a new phenytoin targeting nanopreparation and a preparation method thereof. The nanopreparation for targeting therapy of drug-resistant epilepsy is prepared by taking phenytoin as an active ingredient, a P-glycoprotein monoclonal antibody as a targeting head group and a macromolecular polymer as a carrier. The loading rate and the releasing speed of the phenytoin are controlled by changing the proportion of polyethylene glycol to polycaprolactone in the macromolecular polymer; the problems of poor blood brain barrier permeability, low drug concentration at an epilepsy lesion area, poor treatment effect and serious adverse reaction in the conventional treatment of the drug-resistant epilepsy by the phenytoin are solved by using slow release and active targeting technologies; and the safety of the phenytoin is obviously improved. The preparation can be targeted to the lesion area of the drug-resistant epilepsy, so that the phenytoin content of the lesion area is greatly improved and the seizure of the epilepsy is suppressed.
Owner:AFFILIATED HUSN HOSPITAL OF FUDAN UNIV
Method and system for the prediction of cardiac arrhythmias, myocardial ischemia, and other diseased condition of the heart associated with elevated sympathetic neural discharges
Methods and systems are provided for determining an increased likelihood of the occurrence of a cardiac arrhythmia, myocardial ischemia, congestive heart failure and other diseased conditions of the heart associated with elevated sympathetic neural discharges in a patient. The methods and systems comprise monitoring the sympathetic neural discharges of a patient from the stellate ganglia, the thoracic ganglia, or both, and detecting increases in the sympathetic neural discharges. The methods and systems may further comprise delivering therapy to the patient in response to a detected increase in the sympathetic neural discharge, such as delivering one or more pharmacological agents; stimulating myocardial hyperinnervation in the sinus node and right ventricle of the heart of the patient; and applying cardiac pacing, cardioversion or defibrillation shocks. Pharmacologic agents which may be used in connection with the delivery of include those which are known to exert anti-arrhythmic effect and anti-convulsant agents, such as phenytoin, carbamazepine, valproate, and phenobarbitone. Other pharmacologic agents may be used to treat impending myocardial ischemia and other diseased conditions of the heart associated with elevated sympathetic neural discharges.
Owner:CEDARS SINAI MEDICAL CENT
Risk assessment for phenytoin-induced adverse drug reactions
A method of predicting the risk of a patient for developing phenytoin-induced adverse drug reactions (ADRs), including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), or drug reactions with eosinophilia and systemic symptoms (DRESS) is disclosed. Genetic polymorphisms of CYP2C genes (including CYP2C9, CYP2C19, CYP2C8 and CYP2C18), HLA alleles (including HLA-A*0207, HLA-A*2402, HLA-B*1301, HLA-B*1502, HLA-B*4001, HLA-B*4609, HLA-B*5101, HLA-DRB1*1001 or HLA-DRB1*1502) and phenytoin concentration in the patient's plasma can all contribute to phenytoin-induced ADRs.
Owner:CHANG GUNG MEDICAL FOUND CHANG GUNG MEMORIAL HOSPITAL AT KEELUNG
Composition of cannabidiol and hydantoin antiepileptic drug and use thereof
ActiveCN108245510AReduce or eliminate side effectsImprove complianceNervous disorderHydroxy compound active ingredientsSide effectTreatment effect
The invention discloses a composition of cannabidiol and a hydantoin antiepileptic drug and use thereof. The composition comprises cannabidiol and a hydantoin antiepileptic drug or pharmaceutically acceptable salt thereof, especially a pharmaceutical composition of cannabidiol and phenytoin. The composition can achieve an unexpected synergistic treatment effect when used for treatment of epilepsy,especially partial epileptic seizure, also can alleviate or eliminate the side effect brought about by single use of cannabidiol or phenytoin, and improves the patient compliance.
Owner:HANYI BIO TECH CO LTD
Preparation method of phenytoin homogeneous enzyme immunoassay kit and phenytoin polyclonal antibodies
InactiveCN102807618AStrong specificityHigh potencyImmunoglobulinsMaterial analysisBlood concentrationEnzyme immunoassays
The invention aims at providing a preparation method of high-specificity phenytoin polyclonal antibodies and a phenytoin homogeneous enzyme immunoassay kit. The preparation method comprises the steps of preparing phenytoin specific polyclonal antibodies, preparing phenytoin conjugates labeled by glucose-6-phosphate dehydrogenase, and preparing calibration solution. The specificity of the phenytoin polyclonal antibodies is high, the valence is high, the phenytoin polyclonal antibodies almost do not crossly react with tested thirty-two kinds of common drugs and compounds during drug cross reaction testing, and the phenytoin polyclonal antibodies are suitable for the clinical detection of blood concentration of phenytoin. The sensitivity of the phenytoin drug concentration homogeneous enzyme immunoassay kit is high, samples with concentration being 10ng / ml can be accurately detected and the effective detection range of phenytoin drug concentration is 20ng / ml to 40mug / ml. The kit provided by the invention has the advantages of high accuracy, high recovery rate above 90 percent, convenience, rapidness, low cost, high sensitivity and full automation.
Owner:重庆金域医学检验所有限公司
Compositions and methods for the treatment of wounds
InactiveUS20160303203A1Promote healingGood treatment effectOrganic active ingredientsPeptide/protein ingredientsVitamin CMedicine
The present invention is directed to a wound composition comprising an effective amount of phenytoin and / or an effective amount of vitamin C, and an effective amount of a cell growth stimulating compound. The present invention is further directed to a method of treating a wound in a patient comprising administering an effective amount of phenytoin and an effective amount of vitamin C to the wound.
Owner:MALSHE RES & DEV
Detection method of HLA-B*1502 gene, detection kit and application thereof
The invention belongs to the technical field of biology, and provides a reagent for detecting human leukocyte antigen B site 1502 genotype (HLA-B*1502), application of the reagent in preparation of akit for guiding administration of antiepileptic drugs such as carbamazepine, oxcarbazepine, phenytoin and lamotrigine, a corresponding kit and a detection method of the kit. According to the HLA-B*1502 genotyping, three groups of MIX reaction solutions are detected by adopting a PCR-fluorescent probe method, and target nucleic acid molecules are circularly amplified through an amplification reaction, so that a fluorescence generation group is indirectly combined with an amplified target nucleotide sequence; the amount of fluorescence generated by the fluorescence generation group is determined, and the existence of the target nucleotide is determined. The detection reagent comprises a nucleic acid amplification system of three groups of MIX reaction solutions, wherein the nucleic acid amplification system comprises an upstream primer 1 and a downstream primer 1 which can be combined with target nucleotide, and an upstream primer 2 and a downstream primer 2 which can be combined with the target nucleotide; and three groups of probes 1 and probes 4 of a fluorescence detection system matched with the nucleic acid amplification system.
Owner:上海恩元生物科技有限公司
Methods for detecting phenytoin
InactiveCN102636637AEasy to operateStrong specificityBiological testingSpecific antibodyAmount of substance
The invention discloses two methods for detecting phenytoin. The methods comprise the following steps of: making a sample to be detected in contact with an anti-phenytoin specific antibody; and judging the phenytoin content of the sample according to the combination condition of the substance in the sample to be detected and the antibody, wherein the anti-phenytoin specific antibody is obtained from a phenytoin immunogen immune animal. The two detecting methods are high in specificity, can accurately measure the content of the phenytoin, and provide a proof for real-time monitoring of the clinical medicament concentration of the phenytoin.
Owner:JIAXING JIUQIJIU BIOLOGICAL TECH
Method for constructing trauma animal model and promoting wound healing
ActiveCN106880765AWith insulationWith skin rejuvenationOrganic active ingredientsInorganic active ingredientsInjury mouthCold injury
The invention belongs to the field of medicine and particularly relates to a method for constructing a trauma animal model and promoting wound healing. According to the method for promoting wound healing disclosed by the invention, phenytoin silver, dendrobium officinale and hyaluronic acid are utilized as active ingredients to be externally coating a trauma wound, have effects of stopping bleeding, easing pain, relieving itching, restraining wound bacterial infection, promoting wound healing and reducing scar, can be widely applied for treating varieties of traumas like knife wounds, traumatic injury, burn scald, cold injury and the like, can obviously shortens healing time of varieties of trauma wounds, reduces wound pain and itching and reduces scar area.
Owner:MUDANJIANG MEDICAL UNIV
Wound healing compositions based on cyanoacrylates and 5,5-disubstitutedhydantoins, including phenytoin
ActiveUS20120039838A1Improves wound healingGood techniqueSurgical adhesivesAdhesive dressingsCyanoacrylateMedicine
A monomeric adhesive composition includes a stabilized polymerizable monomer, such as a 1,1-disubstituted monomer, including a cyanoacrylate, and a wound healing agent, wherein the wound healing agent is 5,5-disubstitutedhydantoin, including phenyloin; and a method for making said composition.
Owner:ADHEZION BIOMEDICAL
Preparation technique of fosphenytoin sodium
ActiveCN106279279AReduce contentSimple and fast operationGroup 5/15 element organic compoundsHydroxymethylPhosphoryl chloride
Owner:广安凯特制药有限公司
Macaca fascicularis P450 2B6 medical metabolic enzyme and co-expression recombinant carrier with macaca fascicularis P450 oxidoreductase
The invention discloses cynomolgus monkey P450 2B6 drug metabolizing enzyme and a co-expression recombinant vector of the cynomolgus monkey P450 2B6 drug metabolizing enzyme and cynomolgus monkey P450 oxidoreductase. The cynomolgus monkey P450 2B6 drug metabolizing enzyme can catalyze hydroxylation of bupropion hydrochloride and N end demethylation of 3-methyl benzene phenytoin, a gene sequence of the cynomolgus monkey P450 2B6 drug metabolizing enzyme or a complementary sequence of the cynomolgus monkey P450 2B6 drug metabolizing enzyme is a sequence in SEQ ID NO:1 with the mutation rate of 0-1%. The co-expression recombinant vector of the cynomolgus monkey P450 2B6 drug metabolizing enzyme and the cynomolgus monkey P450 oxidoreductase comprises an open reading frame of the sequence of the cynomolgus monkey P450 2B6 drug metabolizing enzyme and the open reading frame of the sequence of the cynomolgus monkey P450 oxidoreductase. The sequence or the complementary sequence of the cynomolgus monkey P450 oxidoreductase is shown in SEQ ID NO:2. Protein which is expressed by a heterogeneous source of the invention only represents the cynomolgus monkey P450 2B6 hypotype and the system is closet to the real situation of metabolism in vivo of cynomolgus monkeys.
Owner:GUANGZHOU INST OF BIOMEDICINE & HEALTH CHINESE ACAD OF SCI
Composition containing r-aminobutyric acid and antiepileptic drugs
The invention relates to a composition containing r-aminobutyric acid and antiepileptic drugs selected from gabapentin, oxcarbazepine, valproic acid, topiramate, phenytoin and the like, and relates to purposes thereof in the aspects of preventing, delaying or treating the epileptic seizure, in particular resisting epilepsia, scavenging free radicals and restraining lipid peroxidation in the epileptic seizure.
Owner:HUNAN UNIV OF TECH
Composition containing r-aminobutyric acid, taurine and antiepileptic drugs
The invention relates to a composition containing r-aminobutyric acid, taurine and antiepileptic drugs selected from gabapentin, oxcarbazepine, valproic acid, topiramate, phenytoin and the like, and relates to purposes thereof in the aspects of preventing, delaying or treating the epileptic seizure, in particular resisting epilepsia, scavenging free radicals and restraining lipid peroxidation in the epileptic seizure.
Owner:HUNAN UNIV OF TECH
Novel sodium channel blockers
InactiveCN1659136AIsocyanic acid derivatives preparationOrganic compound preparationLymphatic SpreadChannel blocker
The present invention is directed to novel phenytoin derivative compounds and the use of such compounds as sodium channel blockers. Such compositions have utility as anti-cancer agents and can be used to limit or prevent PCa growth and / or metastasis.
Owner:UNIV OF VIRGINIA ALUMNI PATENTS FOUND
Popular searches
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com